Back to homepage

Women’s health

Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies

Authors: Zuramis Estrada Blanco MD, Mariella Lilue MD, Santiago Palacios MD, PhD

The two case studies presented in this article support the findings from a series of retrospective studies, which showed that urinary symptoms improved in women with overactive bladder syndrome who were receiving ospemifene for vulvovaginal atrophy (VVA), a component of genitourinary syndrome of menopause.

More

Experience with ospemifene in a patient with vulvovaginal atrophy and dyslipidemia: a case study

Authors: Silvia Pilar González Rodríguez MD, PhD

This case study reports the experience of a postmenopausal woman with VVA who required escalation from local therapy and presented CVD risk factors (family history and hypertension).

More

Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies

Authors: Mariella Lilue MD, Santiago Palacios MD, PhD, María del Carmen Pingarrón Santofimia MD

Women with breast cancer are at a higher risk of developing vulvar and vaginal atrophy (VVA). Ospemifene is approved to treat VVA in postmenopausal women with a history of breast cancer after completion of all breast cancer (including adjuvant) treatments. This article examines the background characteristics and outcomes in two postmenopausal women with a history of breast cancer who were treated with ospemifene for VVA.

More

Experience with ospemifene in patients with vulvar and vaginal atrophy: case studies with bone marker profiles

Authors: María del Carmen Pingarrón Santofimia MD, Silvia Pilar González Rodríguez MD, PhD, Mariella Lilue MD, Santiago Palacios MD, PhD

In this case report, outcomes in relation to bone homeostasis, bone mineral density (BMD), and osteopenia– osteoporosis are examined in postmenopausal women during treatment with ospemifene for vulvar and vaginal atrophy (VVA), a component of the genitourinary syndrome of menopause.

More

Ospemifene for vulvar and vaginal atrophy: an overview

Authors: Santiago Palacios MD, PhD

This editorial article introduces a Special Focus Issue entitled “Treatment of Vulvar and Vaginal Atrophy: Clinical Experience with Ospemifene”. Ospemifene is a selective estrogen receptor modulator indicated for treatment of moderate-to-severe symptomatic vulvar and vaginal atrophy in postmenopausal women who are not candidates for local vaginal estrogen therapy or have contraindications for estrogen products.

More